ClinicalTrials.gg
Active, not recruitingNCT06101095Updated Sep 30, 2026

A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

A Phase 4 interventional study of Dupilumab and Placebo in Eosinophilic Oesophagitis, sponsored by Sanofi. Active, not recruiting at 30 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing dupilumab in Eosinophilic Esophagitis — 4 open to participants now, 7 under way, 1 of them phase 3. dupilumab · Eosinophilic Esophagitis.

Enrollment
4th of 11
69 · median 47
Started
2023
with 1 other
Phase 4
4 of 11
1 open now
Registered
6th of 11
by date
Lead sponsor
1 of 11
Sanofi

Among the 11 studies testing dupilumab in Eosinophilic Esophagitis, this one is the 4th largest by enrollment, is one of 2 that started in 2023, is one of 4 in phase 4, and was the 6th registered.

Eosinophilic Esophagitis

235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.

Browse Eosinophilic Esophagitis studies →

Open to participants now

4 of the 11 studies testing dupilumab in Eosinophilic Esophagitis are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 42 Eosinophilic Esophagitis studies recruiting now, 12 (29%) set no upper age limit and 27 (64%) stop at 75 or younger; 27 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing dupilumab in Eosinophilic Esophagitis, or all of them as a file.
02

Study summary

This is parallel, Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5 years) to evaluate the effect of dupilumab treatment on esophageal function, and remodeling in adults with eosinophilic esophagitis.

Duration of study period (per participant)

  • Screening period: Up to 12 weeks before Week 0
  • Randomized double-blind period: 24 weeks
  • Open label period: 104 weeks
  • Post Investigational Medicinal Product (IMP) intervention follow-up period: up to 12 weeks or until the participants switch to commercialized dupilumab, whatever comes first.

There will be ten (10) site visits, and five (5) direct-to-participant IMP delivery visits (except if prohibited by local regulatory authorities or if participant is not willing. In this case, IMP will be dispensed at the study site).

Read the detailed description

The duration per participant will be up to 152 weeks.

03

Conditions studied

  • Eosinophilic Oesophagitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A documented diagnosis of EoE by endoscopic .
  • Baseline endoscopic biopsies with a demonstration on central reading of intraepithelial eosinophilic infiltration.
  • History (by participant report) of an average of at least 2 episodes of dysphagia (with intake of solids) per week in the 4 weeks prior to screening.
  • Body weight ≥40 kg.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Other causes of esophageal eosinophilia or the following conditions: hypereosinophilic syndrome or eosinophilic granulomatosis with polyangiitis (Churg Strauss syndrome).
  • Active Helicobacter pylori infection.
  • History of achalasia, Crohn's disease, ulcerative colitis, celiac disease, and prior esophageal surgery.
  • Any esophageal stricture unable to be passed with a standard, diagnostic, 9 to10 mm upper endoscope or any critical esophageal stricture that requires dilation at screening.
  • History of bleeding disorders or esophageal varices.
  • Treatment with swallowed topical within 8 weeks prior to baseline.
  • Initiation or change of a food elimination diet regimen or reintroduction of a previously eliminated food group in the 6 weeks prior to screening.
  • Participation in prior dupilumab clinical study or participants currently treated or have been treated with commercially available dupilumab or to dupilumab per local labelling.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Dupilumab

    Subcutaneous injection (SC) as per protocol

    Drug: Dupilumab

  • Placebo comparator
    Placebo

    SC injection as per protocol

    Drug: Placebo

Interventions

  • Subcutaneous injection (SC) as per protocol

  • DrugPlacebo

    SC injection as per protocol

06

What researchers measure

Primary outcomes

  1. Change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe (EndoFLIP)

    Distensibility plateau provides an assessment of esophageal function. An increase in distensibility plateau indicates an improvement in esophageal function and a decrease in distensibility plateau indicates a worsening of esophageal function.

    Time frame: From baseline to Week 24

Secondary outcomes

  1. Percent change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe

    Distensibility plateau provides an assessment of esophageal function. An increase in distensibility plateau indicates an improvement in esophageal function and a decrease in distensibility plateau indicates a worsening of esophageal function.

    Time frame: From baseline up to Week 24

  2. Absolute change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe

    Distensibility plateau provides an assessment of esophageal function. An increase in distensibility plateau indicates an improvement in esophageal function and a decrease in distensibility plateau indicates a worsening of esophageal function.

    Time frame: From baseline up to Week128

  3. Percent change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe

    Distensibility plateau provides an assessment of esophageal function. An increase in distensibility plateau indicates an improvement in esophageal function and a decrease in distensibility plateau indicates a worsening of esophageal function.

    Time frame: From Baseline up to Week 128

  4. Change from baseline in eosinophilic esophagitis-endoscopic reference score (EoE-EREFS)

    EoE-EREFS, a scoring system for inflammatory and remodeling features of disease. The overall total score ranges from 0 to 18 with higher number indicating worse disease.

    Time frame: From baseline up to Week 128

  5. Change from baseline in eosinophilic esophagitis (EoE-HSS) Grade

    Severity (grade) and extent (stage) of esophageal abnormalities are scored using a 4-point scale (0 normal; 3 maximum change). Higher score indicates greater severity and extent of histological abnormalities.

    Time frame: From Baseline up to Week 128

  6. Change from baseline in EoE-HSS Stage

    Severity (grade) and extent (stage) of esophageal abnormalities are scored using a 4-point scale (0 normal; 3 maximum change). Higher score indicates greater severity and extent of histological abnormalities.

    Time frame: From Baseline up to Week 128

  7. Proportion of participants who achieved peak Esophageal Intraepithelial Eosinophil Count of ≤6 eosinophils/high power field (Eos/HPF)

    Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).

    Time frame: At Weeks 24, 76 and 128

  8. Proportion of participants who achieved peak Esophageal Intraepithelial Eosinophil Count of ≤15 Eos/HPF

    Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).

    Time frame: At Week 24

  9. Proportion of participants who achieved peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/HPF

    Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).

    Time frame: At Weeks 24, 76 and 128

  10. Change from baseline in normalized enrichment score (NES) for EoE diagnostic panel (EDP) transcriptome signature

    NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease).

    Time frame: From baseline up to Week 128 (EOT)

  11. Change from baseline in normalized enrichment score (NES) for type 2 inflammation transcriptome signature

    NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease).

    Time frame: From Baseline up to Week 128 (EOT)

  12. Incidence of treatment-emergent adverse events (TEAEs), and serious adverse events (SAEs)

    Time frame: From the first IMP administration up to end of post treatment follow up period (week139)

  13. Incidence of adverse events of special interest (AESIs)

    Time frame: From the first IMP administration up to end of post treatment follow up period (week139)

07

Study locations

30 sites
  • United Gastroenterologists - Murrieta- Site Number : 8400001
    Murrieta, California 92563, United States
  • University of California San Francisco - Parnassus Heights- Site Number : 8400020
    San Francisco, California 94143, United States
  • Borland Groover Clinic- Site Number : 8400016
    Jacksonville, Florida 32256, United States
  • Treasure Valley Medical Research- Site Number : 8400018
    Boise, Idaho 83706, United States
  • Northwestern University- Site Number : 8400003
    Chicago, Illinois 60611, United States
  • GI Alliance - Glenview- Site Number : 8400012
    Glenview, Illinois 60026, United States
  • Illinois Gastroenterology Group- Site Number : 8400004
    Gurnee, Illinois 60031, United States
  • University of Iowa- Site Number : 8400006
    Iowa City, Iowa 52242, United States
  • University of Massachusetts Chan Medical School- Site Number : 8400019
    Worcester, Massachusetts 01655, United States
  • Mayo Clinic Hospital Rochester- Site Number : 8400008
    Rochester, Minnesota 55905, United States
  • University of North Carolina at Chapel Hill- Site Number : 8400007
    Chapel Hill, North Carolina 27514, United States
  • Cleveland Clinic - Cleveland- Site Number : 8400009
    Cleveland, Ohio 44195, United States
  • Penn Medicine: University of Pennsylvania Health System- Site Number : 8400010
    Philadelphia, Pennsylvania 19104, United States
  • Private Practice - Dr. Martin Yudovich- Site Number : 8400015
    Houston, Texas 77087, United States
  • GI Alliance - Mansfield- Site Number : 8400017
    Mansfield, Texas 76063, United States
  • Itaigara Memorial - Hospital Dia- Site Number : 0760005
    Salvador, Estado de Bahia 41825-010, Brazil
  • Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760006
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Clínica Loema - Unidade I- Site Number : 0760007
    Campinas, São Paulo 13010-001, Brazil
  • Clinica de Alergia Martti Antila- Site Number : 0760001
    Sorocaba, São Paulo 18040-425, Brazil
  • Hospital Alemao Oswaldo Cruz - São Paulo- Site Number : 0760003
    São Paulo, 01323-020, Brazil
  • Investigational Site Number : 1240006
    Vancouver, British Columbia V5Z 1M9, Canada
  • Investigational Site Number : 1240004
    Vancouver, British Columbia V6Z 2K5, Canada
  • Investigational Site Number : 1240002
    Montreal, Quebec H4A 3T2, Canada
  • Investigational Site Number : 3760006
    Haifa, 3104802, Israel
  • Investigational Site Number : 3760002
    Haifa, 3109601, Israel
  • Investigational Site Number : 3760005
    Jerusalem, 9103102, Israel
  • Investigational Site Number : 3760004
    Jerusalem, 9112001, Israel
  • Investigational Site Number : 3760003
    Tel Aviv, 6423906, Israel
  • Investigational Site Number : 7560001
    Wetzikon, 8620, Switzerland
  • Investigational Site Number : 7560002
    Zurich, 8091, Switzerland
08

References and documents

Publications

  • Dellon ES, Savarino EV, Zaghloul S, Angello JT, Zhang M, Raphael BP, Radwan A, Bredenoord AJ. Study design of the phase IV, randomized, placebo-controlled REMOdeling with Dupilumab in Eosinophilic esophagitis Long-term (REMODEL) trial. Ther Adv Gastroenterol. 2025 Oct 9;18:17562848251383782. doi: 10.1177/17562848251383782. eCollection 2025. PubMed 41084592 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Nov 2025, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2023
First posted
Oct 25, 2023
StartActual
Nov 29, 2023
Primary completionActual
Nov 5, 2025
CompletionEst.
Feb 1, 2028
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
1 time frame changed, 1 added
What changed in the outcomes
  • AddedProportion of participants who achieved peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/HPFTime frame: At Weeks 24, 76 and 128
  • Time frameProportion of participants who achieved peak Esophageal Intraepithelial Eosinophil Count of ≤15 Eos/HPFAt Weeks 24, 76 and 128 → At Week 24
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Secondary outcomes 1 time frame changed, 1 added
    What changed in the outcomes
    • AddedProportion of participants who achieved peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/HPFTime frame: At Weeks 24, 76 and 128
    • Time frameProportion of participants who achieved peak Esophageal Intraepithelial Eosinophil Count of ≤15 Eos/HPFAt Weeks 24, 76 and 128 → At Week 24
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06101095
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 25, 2023
Start date
Nov 29, 2023
Primary completion
Nov 5, 2025
Completion
Feb 1, 2028 (estimated)
Last update
Sep 30, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion